Determinants of outcome and safety of intravenous rt-PA therapy in the very old: a clinical registry study and systematic review
Open Access
- 11 October 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 37 (1) , 107-111
Abstract
SIR—The only curative treatment for acute ischemic cerebrovascular syndrome (ACVS) [ 1 ] is rt-PA administered intravenously within 3 h of symptom onset. In France, it has been licensed since 2002, but is not recommended for patients ≥80 years [ 2 ]. As most strokes occur in the elderly, and the life expectancy is increasing, the benefits and risks of thrombolytic treatment are worth evaluating in this group. However, with the exception of the second part of the NINDS rt-PA trial [ 1 ] in which 42 patients ≥80 years were included, patients in this age group have been excluded from most randomised controlled trials [ 3–6 ]. A number of recent clinical experiences have reported that 3-month outcomes are less favourable in patients ≥80 years than in those much younger, despite any evidence of an increased risk of symptomatic intracranial haemorrhage (SICH) [ 7 ].Keywords
This publication has 1 reference indexed in Scilit:
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995